Market Overview

UPDATE: CRT Capital Initiates Coverage on OncoGenex

Related OGXI
Events for the Week of Nov. 17-21, 2014
OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

CRT Capital Thursday morning ratings report included a coverage initiation by analyst Arlinda Lee on Oncogenex Pharmaceuticals (NASDAQ: OGXI) with a Buy rating and price target of $20.

The highlight for OGXI includes phase 3 trials of Curtisen and subsequent partnership with Teva, along with phase 2 trials of Apatorsen.

The report notes "The basis for our Buy rating is our optimism for a positive outcome from ongoing pivotal Phase 3 SYNERGY trial in castrate resistant prostate cancer (CRPC) in mid-2014. We expect FDA filing in 2H14 and approval in 20145. We also expect rapid uptake of custirsen to reach peak 35% penetration the US and 30% in EU."

OGXI closed the previous trading session at $11.51 and is currently trading around the $11.76 mark.

Latest Ratings for OGXI

DateFirmActionFromTo
Apr 2014Stifel NicolausMaintainsBuy
Apr 2014RBC CapitalDowngradesOutperformSector Perform
Apr 2014NeedhamDowngradesStrong BuyBuy

View More Analyst Ratings for OGXI
View the Latest Analyst Ratings

Posted-In: CRT CapitalNews Price Target Initiation Markets Analyst Ratings

 

Related Articles (OGXI + TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters